CNTA - Centessa Pharmaceuticals plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Centessa Pharmaceuticals plc

1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom
44 203 9206789

Full-time employees82

Key executives

NameTitlePayExercisedYear born
Dr. Saurabh Saha M.D., Ph.D.CEO & Director957.67kN/A1977
Dr. Gregory M. Weinhoff M.B.A., M.D., MBAPrincipal Accounting Officer & CFO655kN/A1971
Dr. David M. Chao Ph.D.Chief Admin. Officer655kN/A1968
Ms. Kristen K. Sheppard Esq., J.D.Sr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Iqbal J. Hussain L.L.B.Gen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1981
Ms. Karen M. AndersonChief People OfficerN/AN/A1968
Dr. Antoine Yver M.D., M.Sc., MScExec. VP & Chairman of Devel.N/AN/A1958
Ms. Tia L. BushChief Quality OfficerN/AN/A1971
Dr. David John Grainger Ph.D.Chief Innovation OfficerN/AN/A1969
Dr. Harris L. Rotman Ph.D.Sr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Corporate governance

Centessa Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.